Abstract:Conversion of arachidonic acid epoxides to diols by soluble epoxide hydrolase (sEH) diminishes the beneficial cardiovascular properties of these epoxyeicosanoids. We therefore examined the possible biochemical consequences of inhibition of sEH and sEH deletion. We hypothesized that decreased sEH expression, would increase mitochondrial integrity, insulin sensitivity, EETs isomers and adipocyte function. To test this hypothesis, we examined the effect of sEH inhibitors on human MSC‐decreased adipocytes as well as sEH deletion in a mouse model treated with either HO‐1 lentiviral‐vector or cobalt protoporphyrin (CoPP) over an 8‐week period. Human MSc synthesized both EETs and EET metabolites (DHETs). MSc‐derived adipocyte treated with Auda, an inhibitor of sEH, exhibited a decreased number of large adipocytes, i.e. inflamed adipocyte but an increased number of healthy adipocytes that display increased levels of adiponectin, HO‐1 and PGC‐1a and decreased levels of TNFa. The addition of 8, 9, 14, and 15 EETs to adipocyte culture resulted in a reduction in large inflamed adipocytes, PPARg, FAS and lipid accumulation. In vivo studies demonstrated that sEH deletion resulted in a significant decrease in body weight and fasting glucose; p <0.05 and increased insulin sensitivity and serum adiponectin levels (p<0.03) and decreased visceral fat (p<0.05). Critically, sEH deletion was manifested by a significant increase in EETs isomers 5, 6; 8, 9; 11, 12; and 14, 15, EETs. Additionally, induction of HO‐1 potentiated the increases of EETs isomers, suggesting that increases antioxidant protected EETs from degradation by ROS. These novel observations highlighted the potential beneficial effects of EETs that resulted in increased mitochondrial integrity, HO‐1‐PGC1a and UCP1 levels. These results provide evidence that sEH deletion preserved vascular homeostasis, increased brown fat phenotype and that both EETs‐agonist and sEH inhibitors may have therapeutic potential in the treatment of metabolic syndrome and dyslipidemia. Support or Funding Information National Institutes of Health grant (HL34300 to NGA) This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.

Soluble epoxide hydrolase deficiency attenuates lipotoxic cardiomyopathy via upregulation of AMPK-mTORC mediated autophagy

Soluble Epoxide Hydrolase Inhibition Protected Against Diabetic Cardiomyopathy Through Inducing Autophagy and Reducing Apoptosis Relying on Nrf2 Upregulation and Transcription Activation.

Sulfated Polysaccharides from Enteromorpha prolifera Attenuate Lipid Metabolism Disorders in Mice with High-fat Diet-induced Obesity via an AMPK-dependent Pathway

Cardiomyocyte-specific knockout of endothelin receptor a attenuates obesity cardiomyopathy.

Soluble Epoxide Hydrolase and Ischemic Cardiomyopathy

Ablation of Soluble Epoxide Hydrolase Expression Increases Beige Fat Over White Fat Through an Increase in Mitochondrial Integrity, Insulin Sensitivity and HO‐1‐PGC1α‐adiponectin in‐vitro and in‐vivo

Increased Soluble Epoxide Hydrolase Activity Positively Correlates with Mortality in Heart Failure Patients with Preserved Ejection Fraction: Evidence from Metabolomics.

Opposite Effects of Gene Deficiency and Pharmacological Inhibition of Soluble Epoxide Hydrolase on Cardiac Fibrosis

Inhibition of soluble epoxide hydrolase attenuates a high-fat diet-mediated renal injury by activating PAX2 and AMPK

Sulfated Polysaccharides from Enteromorpha Prolifera Attenuate Lipid Metabolism Disorders in Mice with Obesity Induced by a High-Fat Diet Via a Pathway Dependent on AMP-Activated Protein Kinase.

Inhibition of Soluble Epoxide Hydrolase Ameliorates Hyperhomocysteinemia-Induced Hepatic Steatosis by Enhancing Β-Oxidation of Fatty Acid in Mice.

Pharmacological Inhibition Of Soluble Epoxide Hydrolase Ameliorates Chronic Ethanol-Induced Cardiac Fibrosis By Restoring Autophagic Flux

Deletion of Soluble Epoxide Hydrolase Attenuates Cardiac Hypertrophy Via Down-Regulation of Cardiac Fibroblasts-Derived Fibroblast Growth Factor-2.

Inhibition of Soluble Epoxide Hydrolase Limits Mitochondrial Damage and Preserves Function Following Ischemic Injury.

Prevention And Reversal Of Cardiac Hypertrophy By Soluble Epoxide Hydrolase Inhibitors

Abstract 13865: Cardiac Specific Deletion of Endothelin-1 Receptor a Rescues the Heart from High-Fat Diet-Induced Cardiac Dysfunction Via Regulating Autophagy

Inhibition of Soluble Epoxide Hydrolase Attenuates High-Fat-Diet-Induced Hepatic Steatosis by Reduced Systemic Inflammatory Status in Mice

Pharmacological inhibition or genetic ablation of soluble epoxide hydrolase attenuates obesity-induced nonalcoholic fatty liver disease

Beclin-1 haploinsufficiency ameliorates high fat diet-induced myocardial injury via inhibiting alternative mitophagy

Epicardial Adipose Tissue-Derived Leptin Promotes Myocardial Injury in Metabolic Syndrome Rats Through PKC/NADPH Oxidase/ROS Pathway

EPHX1 mutations cause a lipoatrophic diabetes syndrome due to impaired epoxide hydrolysis and increased cellular senescence